Contingency Management for Smoking Cessation Among Veterans With Schizophrenia or Other Psychoses
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Nicotine Dependence
- Sponsor
- US Department of Veterans Affairs
- Enrollment
- 23
- Locations
- 1
- Primary Endpoint
- Number of treatment sessions attended
- Status
- Terminated
- Last Updated
- 10 years ago
Overview
Brief Summary
This study examines the use of contingent incentives to increase attendance at smoking cessation treatment sessions by smokers with schizophrenia and other psychoses who want to quit smoking. We hypothesize that participants randomized to receive contingent rewards for group attendance will attend more treatment sessions than those in the control group.
Detailed Description
Schizophrenia and other psychotic disorders are highly prevalent in the VA population and are associated with high rates of smoking. Although smoking cessations approaches that work for non-schizophrenic patients such as behavioral counseling and medications appear to be efficacious for schizophrenic smokers, a major obstacle in providing adequate treatment is poor attendance at treatment sessions. Contingency management has been shown to shape treatment behavior in non-schizophrenic smokers and to shape other behaviors such as cocaine use and exercise in schizophrenics. The intention of this project is to examine the use of contingent incentives to increase attendance at smoking cessation treatment sessions by smokers with schizophrenia and other psychoses and to compare two different approaches to providing contingent incentives in this context. Subjects in the experimental condition draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Subjects in the experimental condition receive a set reward that will not change regardless of attendance at consecutive sessions. We hypothesize that the participants in the experimental condition will attend more smoking cessation group therapy sessions than those in the control condition because they will have the possibility, although not the likelihood, to obtain contingent reinforcement of greater value.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All subjects must be diagnosed with schizophrenia or any other psychotic disorder, bipolar disorder with psychotic features, or major depression with psychotic features according to the electronic medical record.
- •Current nicotine use, defined as smoking 5 or more cigarettes/day for at least 16 of the past 30 days prior to study screening.
- •Prospective subjects must indicate willingness to attend smoking cessation group therapy.
Exclusion Criteria
- •Imminent risk for suicide or violence.
- •Severe psychiatric symptoms or psychosocial instability likely to prevent participation in the study protocol (i.e., attendance at scheduled sessions, ability to read study materials, and/or ability to comprehend interventions).
- •Clinically apparent, gross cognitive impairment.
Outcomes
Primary Outcomes
Number of treatment sessions attended
Time Frame: 11 weeks
Secondary Outcomes
- Continuous abstinence from quit date(3 and 6 months)
- Days to relapse from quit date(Up to 6 months)
- Change in BPRS scores(3 and 6 months)
- Change in PHQ-9 scores(3 and 6 months)
- Reduction in cigarettes per day(3 and 6 months)
- 7- and 30-day point prevalence abstinence(3 and 6 months)